NEKTAR THERAPEUTICS WKN: 165417 ISIN: US6402681083 Kürzel: NKTR Forum: Aktien Thema: Hauptdiskussion

Es lebt wieder 😇 bin dabei

https://www.prnewswire.com/news-releases/nektar-announces-promising-new-and-corrected-rezpegaldesleukin-efficacy-data-which-were-previously-reported-in-2022-and-incorrectly-calculated-by-former-collaborator-eli-lilly--company-301894443.html

Die Geschäftszahlen stehen an 😇

Ist noch jemand hier ? 🙋‍♂️

Wisst ihr vielleicht wie hier das Verhältnis Cash Volumen zu Börsenwert ist?

https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-issues-statement-confirming-it-does-not-hold

https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-301758741.html

Naja Cash 💰 ist vorhanden 🤔

Nektar Therapeutics: Another Clinical Failure Nearly Wipes Out The R&D Value https://seekingalpha.com/article/4581825-nektar-therapeutics-another-clinical-failure-nearly-wipes-out-value Summary • Nektar announced that the ISLAND study of rezpeg in lupus failed to meet its primary endpoint and that Lilly would not be advancing the drug into Phase III studies. • Rezpeg continues to show concerning tolerability issues, and I expect Lilly to walk away from the program entirely. • NKTR-255 could emerge as a credible candidate in oncology, but there's too little data available to give it anything more than typical Phase I oncology drug odds of success. • Nektar has more than $500M in cash, but it remains to be seen whether management can buy or develop a drug candidate that can make it to commercialization. • I can understand some speculative appeal given that Nektar currently trades below cash, but speculators need to at least appreciate the risk that the cash is ultimately burned to zero with no benefit to shareholders. ...

Der Absturz ist schon sehr heftig 🤔

https://seekingalpha.com/news/3940432-nektar-therapeutics-plunges-29-after-hours-on-mid-stage-lupus-treatment-failure Nektar Therapeutics plunges 29% after hours on mid-stage lupus treatment failure

Bin ich nicht so sicher - Obwohl die mittlere Dosisstufe eine numerische Verbesserung des SLEDAI-2K-Scores im Vergleich zu Placebo zeigte (mit einem Placebo-angepassten Ansprechen von 8,8 % für die modifizierte Intent-to-treat (mITT)-Population [p = 0,309] und 13,9 % für der Per-Protocol-Population [p=0,06]), wurde der primäre Endpunkt nicht erreicht ‼️

https://www.streetinsider.com/dr/news.php?id=21270503&gfv=1

🎈

https://www.marketscreener.com/amp/quote/stock/NEKTAR-THERAPEUTICS-45013433/news/NEKTAR-THERAPEUTICS-Results-of-Operations-and-Financial-Condition-Regulation-FD-Disclosure-form-42692997/

https://www.prnewswire.com/news-releases/nektar-therapeutics-presents-preclinical-data-from-novel-pegylated-interferon-gamma-program-nktr-288-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-301673971.html